Thrivent Financial for Lutherans Has $38.68 Million Holdings in IDEXX Laboratories, Inc. $IDXX

Thrivent Financial for Lutherans lessened its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 32.6% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 60,538 shares of the company’s stock after selling 29,268 shares during the period. Thrivent Financial for Lutherans’ holdings in IDEXX Laboratories were worth $38,677,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. WealthCollab LLC acquired a new position in shares of IDEXX Laboratories in the 2nd quarter valued at about $30,000. J.Safra Asset Management Corp bought a new stake in IDEXX Laboratories in the third quarter worth approximately $31,000. Armstrong Advisory Group Inc. increased its holdings in IDEXX Laboratories by 55.9% in the third quarter. Armstrong Advisory Group Inc. now owns 53 shares of the company’s stock worth $34,000 after purchasing an additional 19 shares in the last quarter. Salomon & Ludwin LLC acquired a new position in IDEXX Laboratories in the third quarter valued at approximately $35,000. Finally, Ameritas Advisory Services LLC acquired a new stake in shares of IDEXX Laboratories during the 2nd quarter worth approximately $36,000. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Price Performance

Shares of NASDAQ IDXX opened at $639.60 on Tuesday. The stock has a market cap of $51.07 billion, a price-to-earnings ratio of 50.72, a PEG ratio of 3.58 and a beta of 1.67. The company has a debt-to-equity ratio of 0.24, a quick ratio of 0.87 and a current ratio of 1.18. IDEXX Laboratories, Inc. has a fifty-two week low of $356.14 and a fifty-two week high of $769.98. The firm’s 50-day simple moving average is $703.10 and its 200 day simple moving average is $662.65.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Monday, February 2nd. The company reported $3.08 earnings per share for the quarter, beating analysts’ consensus estimates of $2.93 by $0.15. The company had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.07 billion. IDEXX Laboratories had a return on equity of 67.78% and a net margin of 24.65%.The company’s revenue for the quarter was up 14.3% on a year-over-year basis. During the same quarter last year, the company earned $2.53 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. As a group, research analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently issued reports on IDXX. JPMorgan Chase & Co. boosted their target price on shares of IDEXX Laboratories from $675.00 to $775.00 and gave the company an “overweight” rating in a research report on Tuesday, November 4th. Wall Street Zen lowered shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 17th. BTIG Research set a $800.00 target price on IDEXX Laboratories in a research note on Tuesday. Leerink Partners set a $785.00 price target on IDEXX Laboratories in a research note on Monday, November 3rd. Finally, Weiss Ratings cut IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday. Seven analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $760.50.

Insiders Place Their Bets

In other IDEXX Laboratories news, EVP Nimrata Hunt sold 9,425 shares of IDEXX Laboratories stock in a transaction on Friday, November 7th. The shares were sold at an average price of $703.34, for a total transaction of $6,628,979.50. Following the transaction, the executive vice president directly owned 21,149 shares of the company’s stock, valued at $14,874,937.66. The trade was a 30.83% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.98% of the company’s stock.

IDEXX Laboratories News Summary

Here are the key news stories impacting IDEXX Laboratories this week:

• Positive Sentiment: Q4 beat: IDXX posted $3.08 EPS (vs. $2.93 consensus) and $1.091B in revenue (up ~14% YoY), with expanding margins — a sign of continued underlying demand and efficiency. IDEXX Laboratories Announces Fourth Quarter and Full Year 2025 Results
• Positive Sentiment: Management cites resilient demand at vet clinics and higher testing per visit; it says 2026 revenue and profit are expected to come in above Wall Street’s prior estimates. IDEXX forecasts 2026 revenue, profit above estimates on strong demand for pet diagnostics
• Neutral Sentiment: Guidance is mixed: FY?2026 EPS was guided to a range (14.290–14.800) that overlaps the consensus (?14.45), and revenue guidance sits at the low end of estimates ($4.6–4.7B), leaving room for investor interpretation on growth pacing.
• Negative Sentiment: Market reaction: despite the beat, shares sold off in early trading — indicating investors were disappointed by the tone or range of guidance (or rotated out after the run?up). IDEXX Stock Down Despite Q4 Earnings & Revenue Beat, Margins Rise
• Negative Sentiment: Valuation risk: IDXX trades at an elevated P/E, which can amplify downside when guidance is viewed as conservative or when growth expectations are re?priced.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.